Now, Tedder and colleagues help to resolve this issue by showing that B-cell depletion with a CD20-specific antibody has opposing effects on the severity of EAE depending on whether treatment is ...

“While the early acute adverse events in the course of anti-CD20 therapy appear to be a consequence of cytokine release in the course of B cell depletion, later adverse events might be partly ...

DR-0201 is a potential first-in-class CD20-directed bispecific antibody that targets and engages specific tissue-resident and trafficking myeloid cells to induce deep B-cell depletion via targeted ...